Brain insulin may hold key to schizophrenia's cognitive fog
NCT ID NCT05748990
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study investigates whether abnormal insulin action in the brain contributes to cognitive and metabolic problems in schizophrenia. Twenty participants (some with schizophrenia, some healthy) will receive either intranasal insulin or a placebo before a PET scan that measures brain glucose uptake. The goal is to see if brain insulin resistance is linked to thinking and memory challenges in schizophrenia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
intranasal insulin (Humalog)
What this could lead to
If successful, this could reveal a link between brain insulin resistance and cognitive problems in schizophrenia, pointing toward new treatment targets.
What could go wrong
This is a very small, early-stage study (20 people) that only measures brain activity, not clinical outcomes. It may not lead to any treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre for Addiction and Mental Health
RECRUITINGToronto, Ontario, M6J1H3, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact